Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBiotron Ltd

Biotron Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.002 AUD 0.00(0%)
Last update at 2026-11-11T04:57:00Z
VOLUME
220000
Market Cap
5.57M

Momentum Score

…

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biotron Ltd is an Australian clinical-stage biotechnology company focused on developing antiviral therapeutics for human viral infections. Long-term growth drivers include progress through clinical trials, licensing or partnership opportunities and addressing unmet needs in chronic viral diseases, which may benefit from novel mechanisms of action.

The principal investment risks are high clinical and regulatory uncertainty, ongoing funding and dilution risk and limited liquidity that could amplify share-price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.53M
Revenue Per Share
-
Gross Profit TTM
0.53M
Debt / Equity
-0.03
ROE
-87.44%
Net Debt
-1.55M
ROCE
-65.99%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -2.04M -0.32M -3.44M -3.49M -2.78M
Net income -1.52M -0.32M -3.44M -3.49M -2.79M
Selling general administrative - 0.77M 0.53M 0.70M 1.12M
Selling and marketing expenses - 0.74M 0.87M 0.93M -
Gross profit -0.00M 1.81M 1.65M 1.43M -1.26M
Reconciled depreciation - - 0.04M 0.04M 0.05M
Ebit -1.93M -0.34M -5.08M -3.61M -2.78M
Ebitda -1.93M -0.33M -5.04M -3.60M -2.73M
Depreciation and amortization 0.00M 0.00M 0.04M 0.01M 0.05M
Operating income -1.93M -0.34M -5.15M -3.61M -2.78M
Other operating expenses 1.93M 2.15M 5.15M 5.04M 4.34M
Interest expense - 0.01M 0.00M 0.00M 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.02M 0.07M 0.12M 0.00M
Net interest income - - 0.07M 0.12M -0.00M
Income tax expense -0.53M -1.81M -1.65M 1.44M 0.01M
Total revenue - 1.81M 1.65M 1.43M 1.56M
Total operating expenses 1.93M 2.15M 5.11M 5.04M 4.34M
Cost of revenue 0.00M 0.54M 0.04M 3.23M 2.82M
Total other income expense net -0.12M 0.02M 0.07M 0.12M -0.01M
Net income from continuing ops - - -3.44M -3.49M -2.78M
Net income applicable to common shares - -0.32M -3.44M -3.49M -2.78M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 3.74M 0.98M 0.49M 4.14M 1.91M
Intangible assets 2.13M - - - -
Other current assets 0.01M 0.02M 0.02M 0.02M 0.02M
Total liab 0.82M 0.43M 0.74M 0.96M 0.81M
Total stockholder equity 2.92M 0.55M -0.24M 3.17M 1.09M
Other current liab 0.77M 0.34M 0.44M 0.67M 0.44M
Common stock 62.60M 59.32M 56.91M 56.89M 52.84M
Capital stock - - - 56.89M 52.84M
Retained earnings -60.29M -58.77M -58.68M -55.26M -51.84M
Other liab - - - - 0.02M
Other assets - - - 0.05M 0.05M
Cash 1.55M 0.93M 0.39M 3.98M 1.74M
Total current liabilities 0.82M 0.43M 0.74M 0.96M 0.75M
Current deferred revenue - - - -0.04M -0.11M
Net debt -1.55M -0.93M -0.39M -3.94M -1.66M
Short term debt - - 0.01M 0.04M 0.03M
Short long term debt total - - 0.01M 0.05M 0.08M
Other stockholder equity - - - -1.63M -1.01M
Property plant equipment - - - 0.05M 0.09M
Total current assets 1.59M 0.96M 0.43M 4.03M 1.76M
Net tangible assets - - - 3.17M 1.09M
Net receivables 0.02M 0.01M 0.02M 0.02M -
Accounts payable 0.05M 0.09M 0.29M 0.29M 0.39M
Accumulated other comprehensive income 0.62M - 1.52M 1.55M 0.09M
Non currrent assets other - - - 0.05M 0.05M
Non current assets total 2.15M 0.03M 0.07M 0.10M 0.14M
Capital lease obligations - - - 0.05M 0.08M
Long term debt total - - - 0.01M 0.04M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 0.00M - -
Change to liabilities - - - 0.15M 0.20M
Total cashflows from investing activities 0.11M -0.00M 0.00M 0.00M 0.00M
Net borrowings - - - -0.04M -0.03M
Total cash from financing activities 2.29M 1.11M -0.02M 5.53M -0.03M
Change to operating activities - - - -0.03M 0.01M
Net income -1.52M -0.32M -3.44M -3.49M -2.78M
Change in cash 0.62M 0.54M -3.59M 2.24M -2.47M
Begin period cash flow 0.93M 0.39M 3.98M 1.74M 4.21M
End period cash flow 1.55M 0.93M 0.39M 3.98M 1.74M
Total cash from operating activities -1.78M -0.57M -3.57M -3.29M -2.44M
Issuance of capital stock - - 0.02M 6.00M -
Depreciation 0.00M 0.01M 0.04M 0.04M 0.05M
Other cashflows from investing activities - - 0.00M - -
Sale purchase of stock - 1.28M 0.02M -0.43M -0.43M
Other cashflows from financing activities - -0.17M -0.04M -0.04M -0.03M
Change to netincome - - - 0.04M 0.09M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.19M 0.01M -0.18M -2.95M -2.62M
Stock based compensation - - - - 0.01M
Other non cash items -0.07M -0.27M 0.05M 0.16M 0.29M
Free cash flow -1.78M -0.57M -3.57M -3.29M -2.44M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BIT
Biotron Ltd		 -
-%		 0.00 - 11.92 10.59 0.95 358.89 -11.32
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Biotron Ltd

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.

66 Hunter Street, Sydney, NSW, Australia, 2000

61 2 9300 3344

https://www.biotron.com.au

Name Title Year Born
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Exec. Director NA
Mr. Peter James Nightingale B.Econ, CA Company Sec. 1957
Dr. Stephen L. Becker M.D. Chief Medical Officer NA
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…